Chromatography

  • Can Cannabis Boost Cancer Treatments?

Can Cannabis Boost Cancer Treatments?

Aug 10 2018 Read 1685 Times

The medical marijuana industry is quickly gaining momentum, with nations like Canada and the USA at the forefront of the movement. While cannabis is a well-known treatment for conditions like Alzheimer's, Crohn's, chronic pain and anxiety, health experts are now hailing it as a potential booster for pancreatic cancer treatments.

According to scientists, Cannabidiol (CBD), a plant-based medicine extracted from the Cannabis sativa and indica species, can actively enhance the effect of drugs used to treat pancreatic cancer and extend life expectancies by several years.

Fighting cancer with cannabis

As a non-psychoactive CBD doesn't induce a mind-altering "high". Instead, the naturally occurring cannabinoid is shown to have notable anti-inflammatory, analgesic and anti-anxiety properties. A team of researchers from London's Queen Mary University are now building on existing research and claiming that extracts from the herbaceous flowering plant can help boost pancreatic cancer treatments. Currently, just 5% of patients diagnosed with the condition survive for an additional five years, while a huge 80% pass away within 12 months.

“It is very aggressive, so it is very important to find new therapies for this cancer,” asserts Dr Riccardo Ferro, first author of the research.

The findings were published in the journal Oncogene and recount experiments conducted on both Petri dishes and mice that were genetically modified to develop pancreatic cancer. The team found that when exposed to CBD and issued with a chemotherapy drug known as gemcitabine, the life expectancies of mice soared.

A potent cannabis/gemcitabine cocktail

Gemcitabine actively targets GPR55, a G protein-coupled receptor gene linked to the growth and multiplication of pancreatic cancer cells. While placebo group mice lasted 19 days, CBD group mice lasted 25 days and gemcitabine mice lasted 28 days, a combination of gemcitabine and CBD saw mice survive for an average of 53 days after receiving treatment.

The team muse that CBD actively blocks GPR55 gene receptors and stop them from reacting with other substances that trigger the growth and multiplication of cancer cells. Furthermore, they noted CBD impedes gemcitabine resistance which helps the medicine perform better, for longer.

New awareness surrounding therapeutic values of cannabinoids

While medical trials haven't yet been approved, Ferro and his colleagues are optimistic the results can be replicated in humans. The findings have also been welcomed by senior members of the medical community, with Professor David Nutt, a former government adviser on drugs saying, “This is one drop in what I suspect will become a torrent of research findings showing therapeutic value of cannabinoids in a range of cancers".

For more news on the burgeoning medical marijuana industry don't miss 'Good is Not a Number - Challenges in the Cannabis Extraction Manufacturing: Transitioning from Traditional Subjective to Modern QC/QA/PAT Chromatographic Analysis'.

Read comments0

Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.


Digital Edition

Lab Asia December 2018

December 2018

In This Edition Articles - Determination of heroin in street drug samples with printable surface enhanced Raman scattering (P-SERS) - Advances in Protein Sample Preparation: Centrifugation i...

View all digital editions

Events

Smart Factory Expo (SFE 2019)

Jan 16 2019 Tokyo, Japan

Arab Health

Jan 28 2019 Dubai International Convention & Exhibition Centre

Nano Tech 2019

Jan 30 2019 Tokyo, Japan

World Congress on Chromatography

Jan 31 2019 Paris, France

SLAS 2019

Feb 02 2019 Washington, DC, USA.

View all events